The global incidence, deaths, and disability-adjusted life years tied to metabolic dysfunction–associated steatohepatitis (MASH)-related liver cancer have more than doubled in older adults since 1990, with a heavy impact on low- and middle-income countries.
FDA Approves Semaglutide for MASH With Fibrosis
Gallbladder Removal With 3-Plus Risk Factors May Increase MASLD Risk
TACE Plus SBRT Effective in Large Tumors Caused by HCC
Dietary Inflammatory Index Not Linked to Liver Fibrosis or Fatty Liver Index in MASLD
Global Burden of MASH-Related Liver Cancer Rising Sharply Among Older Adults
Early Identification of MASLD/MASH Saves Lives: Naim Alkhouri, MD
Increased Awareness, Novel Interventions Spell New Era for MASLD/MASH: Naim Alkhouri, MD
New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD
Surgeries and Endoscopic Procedures Offer Different Benefits for MASLD
Weight Loss Drug HU6 Shows Promise in MASH With Muscle-Sparing Benefits
Air Pollution, Obesity Linked to Significant Liver Fibrosis in Patients With MASH
Alarming Rise in Liver Disease Amid Global Fatty Liver Day 2025
Calorie Consumption Tied to Mortality Risk in Men With MASLD
Semaglutide May Reduce Liver Fibrosis in Patients With MASH
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD
New Developments Warrant Rethinking HCC Transplant Criteria
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
Pegbelfermin Shows Promise in Addressing Liver Fibrosis in MASH
MASLD Associated With 2-Fold Increase of Serious Bacterial Infection
GLP-1 RAs May Offer Broad Hepatic Benefits in MASH
New Therapies Expanding the MASH Treatment Landscape
MASH Clinical Trials Historically Underrepresent Certain Groups
Lipid Metabolites Emerge as Noninvasive Diagnostic Tool in MASH
Mortality Declines but Incidence Rates Up for Cirrhosis and Other Chronic Liver Diseases
Promising Potential for FGF21 Analogs in MASH Management
MASH-Related PLC on the Rise in Young Adults
"Alarming Rise" of Global MASH-Related Primary Liver Cancer Incidence Since 2000
A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins
Top 5 Most-Viewed Liver Cancer Content for 2024
Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation
Patients With HCC May Avoid Additional Treatment After Complete Response
Real-World Results of Durvalumab/Tremelimumab in U-HCC Show Promise Despite Line of Therapy
Study Highlights Increasing Global Health Burden of Liver Cancer
ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments
